Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.

Sedláková I, Vávrová J, Tošner J, Hanousek L

Department of Gynecology and Obstetrics, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic. sedlakiva@seznam.cz

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n=81; median (med), 11.53 μmol/l; range, 1.78-43.21 μmol/l) compared with controls with no ovarian pathology (n=27; med, 1.86 μmol/l; range, 0.94-9.73 μmol/l), and patients with benign ovarian tumor (n=51; med, 6.17 μmol/l; range, 1.12-25.23 μmol/l; P<0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.

Published 24 March 2011 in Tumour Biol, 32(2): 311-6.
Full-text of this article is available online (may require subscription).

Articles on Ovarian Cancer published 24 March 2011:

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.   Tumour Biol, 32(2): 311-6.

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. ... [Abstract] [Full-text]

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.   Tumour Biol, 32(2): 311-6.

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. ... [Abstract] [Full-text]

Articles on Ovarian Cancer published 17 March 2011:

Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease.   Cochrane Database Syst Rev, 3: CD007584.

[Abstract] [Full-text]

Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease.   Cochrane Database Syst Rev, 3: CD007584.

[Abstract] [Full-text]

FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.   Am J Surg Pathol, 35(4): 484-94.

Sex cord-stromal tumors (SCSTs) of the ovary are relatively uncommon tumors. Diagnosis of SCST rests primarily on the histomorphology of these tumors, and tumors with an atypical or unconventional appearance can pose diagnostic challenges. Previously, we had identified FOXL2 (402C→G) mutation as being characteristic of adult granulosa cell tumors (aGCTs). However, molecular screening for this mutation is not always possible and adds time and cost to the diagnostic process. In this study, we ... [Abstract] [Full-text]

Articles on Ovarian Cancer published 9 March 2011:

Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.   Cancer Lett, 304(1): 21-32.

Cisplatin, as a first-line drug in the chemotherapy of ovarian cancer, poses significant problems in its toxicity to normal tissue and drug resistance. Here, we report that Tetrandrine, with potent anti-cancer effect, significantly enhances the cytotoxicity of cisplatin in ovarian cancer. The in vitro assay indicates that Tetrandrine can markedly increase growth suppression and apoptosis induced by cisplatin and cause redistribution of the cell cycle. Further assay indicates that modulation of ... [Abstract] [Full-text]

Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.   Int J Cancer, 128(9): 2063-74.

Common germline genetic variation in the population is associated with susceptibility to epithelial ovarian cancer. Microcell-mediated chromosome transfer and expression microarray analysis identified nine genes associated with functional suppression of tumorogenicity in ovarian cancer cell lines; AIFM2, AKTIP, AXIN2, CASP5, FILIP1L, RBBP8, RGC32, RUVBL1 and STAG3. Sixty-three tagging single nucleotide polymorphisms (tSNPs) in these genes were genotyped in 1,799 invasive ovarian cancer cases ... [Abstract] [Full-text]

Articles on Ovarian Cancer published 4 March 2011:

Effect of bisphenol-A on the expression of selected genes involved in cell cycle and apoptosis in the OVCAR-3 cell line.   Toxicol Lett, 202(1): 30-5.

To support the argument that bisphenol-A (BPA) poses a risk for ovarian cancer, OVCAR-3 cell line was exposed to environmentally relevant concentration of BPA. Expression of selected genes involved in cell cycle and apoptosis were evaluated by real-time PCR. In a dose-dependent manner, BPA increased OVCAR-3 cell proliferation and decreased caspase-3 activity, but it had no effect on DNA fragmentation. We noted 1.2-1.5-fold induction of genes responsible for inducing cell proliferation and ... [Abstract] [Full-text]

© 2004-2011 Ovarian Cancer Research Today. All Rights Reserved.